MetaCap

Anika Therapeutics Inc. (ANIK)

NASDAQ: ANIKHealth CareMedical/Dental InstrumentsUSD

13.23-0.05 (-0.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANIK stock chart

Technical analysis

Key statistics

All statistics
Market cap
$177.22M
EPS (TTM)
-$0.03
52-week range
9.01 – 22.88
Day range
12.98 – 13.70
Volume / Avg
166.48K / 105.68K
Beta
—

52-week range

$9.01$22.88

ANIK stock today

On Nov 20, ANIK ended the session at $13.23, shedding $0.05 (0.38%), versus the S&P 500's 3.70% decline. Shares are 42.2% below their 52-week high of $22.88, set on Aug 10, 2026 and 46.8% above the 52-week low of $9.01, in the middle of the past year's range. ANIK is up 37.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 33.9%.

Anika Therapeutics has posted a net loss over the last twelve months (EPS of -$0.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Anika Therapeutics

Company profile

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products.

Industry
Medical/Dental Instruments
CEO
Mr. Stephen D. Griffin
Headquarters
Bedford, MA
Employees
235
Website
anika.com

Financial highlights

Full financials

In fiscal 2025, Anika Therapeutics generated $112.8 million in revenue, down 5.9% from fiscal 2024, its first annual decline since 2024. Anika Therapeutics reported a net loss of $10.9 million, compared with a loss of $56.4 million a year earlier. Gross margin was 56.6% (down from 63.4%) and operating margin -9.8%.

Anika Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$112.82M$119.91M$120.79M$113.83M$147.79M
Growth-5.91%-0.73%+6.12%-22.98%+13.29%
Net income$-10.88M$-56.38M$-82.67M$-14.86M$4.13M
EPS (diluted)$-0.76$-3.83$-5.64$-1.02$0.28

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$20.00+51.17%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.00High $23.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$-0.01 vs $0.02
Surprise
-150.00%

ANIK news

All ANIK news

Anika Therapeutics peers

Health Care sector
ANIK peer companies
CompanyPrice% ChgMarket capCompare
UTMDUtah Medical Products Inc.69.49-2.07%$198.01Mvs ANIK
PDEXPro-Dex Inc.63.00-0.77%$201.60Mvs ANIK
KTWOK2 Capital Acquisition Corporation Class A10.130.00%$203.02Mvs ANIK
KRMDKORU Medical Systems Inc.3.19-7.27%$138.37Mvs ANIK
CLPTClearPoint Neuro Inc.6.91-5.47%$221.49Mvs ANIK
PYPDPolyPid Ltd.6.12-6.56%$129.29Mvs ANIK
PROFProfound Medical Corp.6.38-3.19%$233.68Mvs ANIK
STIMNeuronetics Inc.1.25+0.81%$120.60Mvs ANIK

Indexes, lists and sector

Anika Therapeutics stock FAQ

What is Anika Therapeutics's stock price today?

ANIK last traded at $13.23 as of Nov 20, 4:00 PM EST, down 0.38% on the day. Prices are delayed at least 15 minutes.

Who is Anika Therapeutics's CEO?

Mr. Stephen D. Griffin is the chief executive officer of Anika Therapeutics Inc., which has about 235 employees.

What is the ANIK 52-week high?

The 52-week high for ANIK is $22.88 and the 52-week low is $9.01. The stock is currently 42.2% below its high.

Compare ANIK